tbuckley/cabot-search huggingface dataset:
INNV-10. TUMOR TREATING FIELDS (TTF) AS MAINTENANCE THERAPY FOR AN OLIGODENDROGLIOMA CASE AND LONG-TERM FOLLOW-UP
Authors: Uvin Ko, Steven Du, Matthew Moldenhauer, Xiao-Tang Kong
Journal: Neuro-Oncology (2021)

Abstract INTRODUCTION Recurrence of low- and high-grade gliomas is observed often after radiation and chemotherapy. Despite continued research on glioma management, there is limited knowledge regarding maintenance treatment after standard care. Tumor Treating Fields as maintenance therapy after radiation and chemotherapy may potentially help prevent recurrence. CASE REPORT In 2011, a 35-year-old male reported headaches to a local ED. A non-enhancing mass was detected on his brain MRI. Observation was advised by his local surgeon. The patient presented with seizures in early 2014, and his brain MRI found the mass developed new enhancement. In late 2014, the patient had multiple seizures, and significant progression of the tumor was discovered. The patient underwent craniotomy and biopsy in the middle cerebral artery distribution area in early 2015. Pathology reported grade II oligodendroglioma; however, the patient only underwent a biopsy, which might have missed the high-grade glioma region. His brain MRI showed a significant enhancing lesion with rapid growth, which was clinically more consistent with grade III oligodendroglioma. Radiation therapy was conducted followed by 6 cycles of PCV chemotherapy throughout 11 months. Post-radiation-chemotherapy brain MRI was stable with a moderate size residual tumor at the right insula region. Following patient wishes, NovoTTF-100A, or Optune, was administered 6 weeks after completion of chemotherapy as maintenance therapy for 2 years to prevent tumor progression. Now, after 3 years being off Optune, the patient is stable without new neurological symptoms or tumor progression. DISCUSSION: Our case highlights the potential effect of Tumor Treating Fields as maintenance therapy after initial radiation and chemotherapy for low- and high-grade oligodendrogliomas. The patient had rapid tumor progression prior to diagnosis and only underwent a biopsy without resection, yet uncommonly, has survived since initial image diagnosis 10 years ago and tissue diagnosis 6 years ago and is fully functional currently.
Abstract 9299: Associations Between Precipitation and Racial/Ethnic-Specific Adult Cardiovascular Disease Mortality During Wintertime in Northeast United States
Authors: Haris Majeed
Journal: Circulation (2021)

Introduction: Minority (i.e. non-Hispanic (NH) Blacks) populations tend to have higher rates of chronic diseases in comparison to NH Caucasians, leading to early cardiovascular disease (CVD) death. Studies suggest that winter precipitation (rain/snow) is associated with an increased risk of adult CVD mortality. Whether winter precipitation is associated with race/ethnic (RE)-specific CVD mortality remains unknown. Hypothesis: RE-specific associations between winter precipitation and CVD mortality would be strongest for NH Blacks. Methods: Using a population-based design, CDC data was obtained for Northeast US (New York, New Jersey, Pennsylvania). Region- and RE-specific (NH Blacks &amp; Whites, Asian, Latino) adult (35-74 years) CVD mortality for winter months (December-February) from 2011-2019 were recorded based on ICD-10 codes (I00-I99). With population estimates, winter CVD rates were derived. Adjusting for the trend, temperatures, percent inactivity, obesity, college education, income, and region; negative binomial regression was used to associate winter precipitation and CVD rates. Results: From 2011-2019, 84,100 winter CVD adult deaths were recorded in Northeast US. A 1-inch rise in winter precipitation was significantly associated with an increased risk in CVD deaths only for NH Blacks (adjusted rate ratio [RR] 1.02; 95% CI 1.01-1.05) in Northeast US (Fig 1). Whereas the covariate, winter temperatures (per 1 o C rise) was significantly associated with a decrease in CVD only for NH Blacks (RR 0.99; 95% CI 0.98-0.99) and NH Whites (RR 0.99; 95% CI 0.98-0.99). Insignificant interactions were observed between winter precipitation and temperature. Conclusions: Winter rainy/snowy conditions are associated with increased risk of CVD events among NH Black adults. This suggests that climate effects on CVD may differ by RE and highlights the importance for incorporating RE diversity in combination with climatological influences when studying CVD risks.
Identification of a Novel Drug Sensitivity Biomarker Neuregulin-2 for Venetoclax in Non-t(11;14) Multiple Myeloma
Authors: Yujun Dai, Xue-Ping Li, Fang Hu, Jinyuan Li, Yang Liang, Da-Wei Wang, Zhongjun Xia, Xiaoqin Chen
Journal: Blood (2021)
KLF2 regulates neutrophil activation and thrombosis in cardiac hypertrophy and heart failure progression
Authors: Xinmiao Tang, Peiwei Wang, Rongli Zhang, Ippei Watanabe, Eugene Chang, Vinesh Vinayachandran, Lalitha Nayak, Stephanie Lapping, Sarah Liao, Annmarie Madera, David R. Sweet, Jiemeng Luo, Jinsong Fei, Hyun-Woo Jeong, Ralf H. Adams, Teng Zhang, Xudong Liao, Mukesh K. Jain
Journal: Journal of Clinical Investigation (2021)

It is widely recognized that inflammation plays a critical role in cardiac hypertrophy and heart failure. However, clinical trials targeting cytokines have shown equivocal effects, indicating the need for a deeper understanding of the precise role of inflammation and inflammatory cells in heart failure. Leukocytes from human subjects and a rodent model of heart failure were characterized by a marked reduction in expression of Klf2 mRNA. Using a mouse model of angiotensin II–induced nonischemic cardiac dysfunction, we showed that neutrophils played an essential role in the pathogenesis and progression of heart failure. Mechanistically, chronic angiotensin II infusion activated a neutrophil KLF2/NETosis pathway that triggered sporadic thrombosis in small myocardial vessels, leading to myocardial hypoxia, cell death, and hypertrophy. Conversely, targeting neutrophils, neutrophil extracellular traps (NETs), or thrombosis ameliorated these pathological changes and preserved cardiac dysfunction. KLF2 regulated neutrophil activation in response to angiotensin II at the molecular level, partly through crosstalk with HIF1 signaling. Taken together, our data implicate neutrophil-mediated immunothrombotic dysregulation as a critical pathogenic mechanism leading to cardiac hypertrophy and heart failure. This neutrophil KLF2-NETosis-thrombosis mechanism underlying chronic heart failure can be exploited for therapeutic gain by therapies targeting neutrophils, NETosis, or thrombosis.
Prognostic Significance of <i>DDX41</i> Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study
Authors: Nicolas Duployez, Matthieu Duchmann, Laetitia Largeaud, Juliette Lambert, Audrey Bidet, Emmanuelle Clappier, Xavier Thomas, Stephane de Botton, Claude Gardin, Christian Recher, Arnaud Pigneux, Raphael Itzykson, Claude Preudhomme, Hervé Dombret, Eric Delabesse, Marie Sebert
Journal: Blood (2021)
Bifidobacterium adolescentis regulates catalase activity and host metabolism and improves healthspan and lifespan in multiple species
Authors: Shujie Chen, Luyi Chen, Yadong Qi, Jilei Xu, Qiwei Ge, Yuedan Fan, Du Chen, Yawen Zhang, Lan Wang, Tongyao Hou, Xiaohang Yang, Yongmei Xi, Jianmin Si, Lijun Kang, Liangjing Wang
Journal: Nature Aging (2021)
Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731
Authors: Amanda M. Li, Karen R Rabin, John Kairalla, Cindy Wang, Meenakshi Devidas, Olga Militano, Maki Okada, Johann K Hitzler, Anne L Angiolillo, Elizabeth A. Raetz, Mignon L. Loh, Sumit Gupta, Rachel E. Rau
Journal: Blood (2021)
Outcomes in Relapsed/Refractory Burkitt Lymphoma: A Multi-Centre Canadian Experience
Authors: Farheen Manji, Eric Chow, Alina S. Gerrie, Neil Chua, Robert Puckrin, Douglas A. Stewart, Pamela Skrabek, Isabelle Bence-Bruckler, Mary-Margaret Keating, Joanne Britto, Gwynivere A Davies, Vishal Kukreti, John Kuruvilla, Michael Crump
Journal: Blood (2021)
Effect of Steroid Treatment on the Diagnostic Yield of Baseline PET CT in Aggressive B Cell Lymphoma
Authors: Karyn Revital Geiger, Oren Pasvolsky, Tamar Berger, Pia Raanani, Tzippy Shochat, Ronit Gurion, Tamar Anati, David Groshar, Anat Gafter-Gvili, Hanna Bernstine
Journal: Blood (2021)
Abstract 10544: A Gene Expression Signature Reflective of Exposure to Antiplatelet Therapy is Associated with Bleeding
Authors: Kevin A Friede, Rachel MYERS, Jordan Gales, Ilya Zhbannikov, Thomas Ortel, Svati H Shah, William E Kraus, Geoffrey S Ginsburg, Deepak Voora
Journal: Circulation (2021)

Introduction: Biosignatures composed of gene expression data hold promise for personalized antiplatelet therapy in conjunction with current guidelines and risk scores. The Aspirin Response Signature (ARS) of blood RNA transcripts is associated with lower platelet function after exposure to aspirin 325mg and increased risk of major adverse cardiovascular events (MACE). We studied a challenge cohort to determine if exposure to aspirin 81mg and ticagrelor changes ARS scores and a clinical cohort to determine whether ARS scores are associated with incident bleeding. Methods: Samples of whole blood and platelet-rich plasma (PRP) were collected from volunteers enrolled in a challenge study (N=188) who were sequentially exposed to 4 weeks of daily aspirin 81mg, then 325mg, then ticagrelor 90mg twice daily. ARS scores were calculated from whole blood RNA qPCR; platelet function and protein expression were assessed in PRP. ARS scores were also calculated in patients undergoing cardiac catheterization (N=1421). Results: In mixed models assessing the effect of antiplatelet drug exposure, exposure to aspirin 81mg was not associated with changes in ARS component gene expression or ARS score. Exposure to aspirin 325 mg resulted in an increase of 6.0% in aggregate ARS component gene expression (p&lt;3x10 -4 vs baseline and vs aspirin 81mg) and an increase in expression of platelet proteins corresponding to ARS genes. Exposure to ticagrelor resulted in an increase of 30.7% in ARS component gene expression (p&lt;1x10 -10 vs baseline and each aspirin dose) and ARS score (p&lt;6x10 -4 vs baseline and each aspirin dose). In the catheterization cohort, 25.4% of patients experienced bleeding events over a median 6.2 years of follow up. In a Cox model adjusting for demographics and baseline antithrombotic medication use, patients with ARS scores above the median had a higher risk of incident bleeding (HR 1.26 [95% CI 1.01-1.56], p = 0.038). Conclusions: The ARS gene expression score increased in response to exposure to antiplatelet agents with different mechanisms of action in a dose- and potency-dependent fashion and was associated with increased bleeding risk. ARS scores could inform future strategies to individualize antiplatelet therapy to balance prevention of bleeding and MACE.
Association of Individual and Familial History of Correctional Control With Health Outcomes of Patients in a Primary Care Center
Authors: Onagh MacKenzie, Jacqueline Goldman, Madeline Chin, Bridget Duffy, Sarah Martino, Susan Ramsey, Monik C. Jiménez, Rahul Vanjani
Journal: JAMA Network Open (2021)

Research has shown that experiences of incarceration, probation, and parole are associated with worse health outcomes for incarcerated individuals and their families. To quantify the proportion of patients in an urban primary care clinic with an individual or family history of incarceration, probation, and/or parole and to evaluate how correctional control is associated with subjective and objective health outcomes. This cross-sectional, mixed-methods study used patient surveys and retrospective medical record review to assess the experience of correctional control among 200 English-speaking adult patients presenting for care at the Rhode Island Hospital Center for Primary Care between July 9, 2019, and January 10, 2020. Patient surveys included closed and open-ended questions pertaining to personal or familial experiences of incarceration, probation, and parole, as well as health outcomes associated with these experiences. Medical record review abstracted key health indicators and health care use data. In this cross-sectional study of 200 adult patients (1 participant was removed from the full analytic sample owing to missing ethnicity data; 113 of 199 men [56.8%]; mean [SD] age, 51.2 [14.0] years) presenting for primary care, 78 of 199 (39.2%) had a history of incarceration, 32 of 199 (16.1%) were on probation or parole at the time of the study, and 92 of 199 (46.2%) reported having a family member with a history of incarceration. Of the 199 patients, 62 (31.2%) identified as non-Hispanic Black, 93 (46.7%) identified as non-Hispanic White, and 44 (22.1%) identified as belonging to another race (American Indian and Alaska Native, Asian, Native Hawaiian and Other Pacific Islander, or other nonspecified). Compared with participants without a history of correctional control, those with a personal history of incarceration were at greater odds of having an emergency department visit that did not result in hospitalization in models adjusted for age, sex, and race and ethnicity (odds ratio, 2.87; 95% CI, 1.47-5.75). This cross-sectional study suggests that primary care clinicians should screen for correctional control as a prevalent social determinant of health.
Bispecific CAR-T Cells Targeting Both BCMA and CD24: A Potentially Treatment Approach for Multiple Myeloma
Authors: Fumou Sun, Yan Cheng, Bailu Peng, Hongwei Xu, Frits van Rhee, Siegfried Janz, Guido Tricot, John D Shaughnessy, Fenghuang Zhan
Journal: Blood (2021)
First Interim Analysis of the Italian Dante Study: De-Escalation before Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with First-Line Nilotinib
Authors: Massimo Breccia, Elisabetta Abruzzese, Fabio Stagno, Alessandra Iurlo, Fabrozio Pene, Immacolata Attolica, Paolo Sportoletti, Patrizia Pregno, Sara Galimberti, Barbara Scappini, Roberto M. Lemoli, Sergio Siragusa, Isabella Capodanno, Francesca Chiodi, Giuseppe Nicola Saglio, Gianantonio Rosti
Journal: Blood (2021)
Abstract 8937: Type 2 Diabetes Significantly Modulates the Power of Lipoprotein(a) to Predict Cardiovascular Events and Mortality in Young Coronary Artery Disease Patients
Authors: Arthur Mader, Maximilian Maechler, Barbara Larcher, Lukas Sprenger, Beatrix Mutschlechner, Magdalena Benda, Andreas Leiherer, Axel Muendlein, Alexander Vonbank, Heinz Drexel, Christoph H Saely
Journal: Circulation (2021)

Introduction: Lipoprotein(a) [Lp(a)] is an important cardiovascular risk factor especially in young individuals. Hypothesis: We hypothesize that Lp(a) has the power to predict cardiovascular events in young coronary artery disease (CAD) patients with type 2 diabetes (T2DM). Methods: Lp(a) was measured in a cohort of 731 patients with angiographically proven CAD who were aged &lt;65 years. Vascular events were recorded over a mean follow-up of 6.6±3.2 years. At baseline, 216 patients had T2DM, and 515 did not have diabetes. Results: During follow-up, 30.2% of our patients suffered cardiovascular events. Lp(a) proved to be a strong and independent predictor of vascular events in the total study cohort (standardized adjusted HR=1.30 [1.07-1.56]; p=0.007). In subgroup analyses by diabetes status, Lp(a) significantly predicted vascular events in non-diabetic patients (standardized adjusted HR= 1.39 [1.12-1.74]; p=0.003) but not in diabetic patients (standardized adjusted HR=0.93 [0.63-1.38]; p=0.731). An interaction term Lp(a)xT2DM was significant (p=0.002), indicating that T2DM significantly modulated the power of Lp(a) to predict cardiovascular events. Conclusions: We conclude that Lp(a) significantly modulates the power of Lp(a) to predict cardiovascular events in CAD patients &lt;65 years.
Magrolimab plus Azacitidine Versus Azacitidine plus Placebo in Untreated Higher Risk Myelodysplastic Syndrome: The Phase 3, Randomized, ENHANCE Study
Authors: G Garcia-Manero, N Daver, J Xu, M Chao, T Chung, A Tan, Y Wang, A Wei, P Vyas, D Sallman
Journal: American Journal of Hematology (2021)
Projected US Urology Workforce per Capita, 2020-2060
Authors: Catherine S. Nam, Stephanie Daignault-Newton, Kate H. Kraft, Lindsey A. Herrel
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Projections to 2035 have demonstrated concern regarding a worsening urology workforce shortage. <h3>Objective</h3> To project the size and demographic characteristics of the urology workforce per capita into 2060 and to anticipate the timing and degree of the impending urology workforce shortage. <h3>Design, Setting, and Participants</h3> This population-based cross-sectional study used the 2019 American Urological Association Annual Census data and the Accreditation Council for Graduate Medical Education's Data Resource Book from 2007 to 2018. The cohort included practicing urologists in 2019. US Census data were used to approximate the projected US population. Data analysis was performed from June 2020 to March 2021. <h3>Exposures</h3> Continued growth stock and flow model of 13.8% and stagnant growth model of 0% increase of the incoming urology workforce with cohort projection per projected US population. <h3>Main Outcomes and Measures</h3> The primary outcome was urology workforce projection per the population aged 65 years and older. Urology workforce projections per capita and demographic characteristics of the urology workforce up to 2060 were calculated under guided assumptions with 2 stock and flow models. <h3>Results</h3> In 2019, there were 13 044 urologists (11 758 men [90.1.%]; 1286 women [9.9%]; median age range, 55-59 years), with 3.99 urologists per 100 000 persons and 311 new urologists entering the workforce. In a continued growth model, 2030 will have the lowest number of urologists per capita of 3.3 urologists per 100 000 persons, and recovery to baseline will occur by 2050. There are 23.8 urologists per 100 000 persons aged 65 years and older in 2020, which decreases to 15.8 urologists per 100 000 persons aged 65 years and older in 2035 and never recovers to its baseline level by 2060. In a stagnant growth model, there will be a continued decrease of urologists per capita to 3.1 urologists per 100 000 persons by 2060. There is a continued decrease in per capita urologists at each time point, with 13.1 urologists per 100 000 persons aged 65 years and older by 2060. <h3>Conclusions and Relevance</h3> With the impending urology workforce shortage, there will be an exaggerated shortage of total urologists per persons aged 65 years and older in both models. This projection highlights the need for structural changes and advocacy to maximize the available urology workforce.
Why Is Aducanumab Priced at $56,000 per Patient? Lessons for Drug-Pricing Reform
Authors: James C. Robinson
Journal: New England Journal of Medicine (2021)

Interview with Dr. James Robinson on the aducanumab experience and the structural factors responsible for high drug prices in the United States. (10:44)Download Aducanumab's price can inform the drug-pricing policy debate because it responds to key features of the market environment for physician-administered drugs: Medicare's reimbursement formula, payment to physicians for infused drugs, and cost-sharing requirements.
Impact of Ethnic Origin on CRISPR/Cas Off-Target Prediction for Guide RNAs Used in Gene Therapy for Sickle Cell Disease and Other Genetic Diseases
Authors: Davi Coe Coe Torres, Karina Griesi-Oliveira, Karina Tozatto-Maio, Andrea Laurato Sertié, Mariana Morato Marques, Priscila Keiko Matsumoto Martin, Mariana Benicio, Barbara Ferri Moraschi, Lucas Assis Pereira, Luiz Vicente Rizzo, Ricardo Weinlich
Journal: Blood (2021)
Deleterious Germline Variants Are Present in Patients with Myelodysplastic Syndrome of All Ages Treated with Related Allogeneic Stem Cell Transplantation
Authors: Simone K. Feurstein, Amy M. Trottier, Noel Estrada-Merly, Matthew Pozsgai, Kelsey McNeely, Michael W. Drazer, Bart L. Scott, Betul Oran, Coleman Lindsley, Ryotaro Nakamura, Ronald M. Sobecks, Soyoung Kim, Stephen R. Spellman, Wael Saber, Lucy A. Godley
Journal: Blood (2021)
Updated Outcomes during the Pandemic: Relationship between CD34and CD3 Cell Doses, One-Year Graft-Versus-Relapse-Free-Survival, Graft-Versus-Host Disease, and Overall Survival in Haploidentical Hematopoietic Stem Cell Transplantation Using Post Transplant Cytoxan: A Single Center Experience
Authors: Anastasia Martynova, Krithika Chennapan, Jack Rodman, Mindy Hsiao, Abdullah Ladha, Eric Tam, Karrune Woan, Preet M. Chaudhary, George Yaghmour
Journal: Blood (2021)
Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature
Authors: Paula Restrepo, Sherry Bhalla, Adolfo Aleman, Violetta Leshchenko, Sarita Agte, Yogita Ghodke-Puranik, Joy Jiang, Mark M. Stevens, Deepu Madduri, Joshua Richter, Shambavi Richard, Ajai Chari, Hearn Jay Cho, Sundar Jagannath, Christopher J Walker, Yosef Landesman, Alessandro Lagana, Samir Parekh
Journal: Blood (2021)
COP26 diary: at last, a dinner
Authors: Richard Smith
Journal: BMJ (2021)

My only commitments of today are a meeting with an Indian friend and a dinner, but I become involved in the determination of the "health people" in the blue zone at COP26, perhaps 50-100 of us, to get Alok Sharma, the president of COP26, to receive the healthy prescription letter signed by health organisations representing 46 million health workers and brought from Geneva to Glasgow by cycling health workers. 1 Sharma, I imagine, must be in a bunker somewhere in the innermost and most well guarded sanctum of COP26.I doubt he's eating a healthy diet, sleeping well, or exercising.He's more likely presiding over a disaster than a triumph and besieged by messages from people demanding the earth, the oceans, and the stars.It seems unlikely that he has actively rebuffed us, more likely no message of ours has ever reached him.
Clonal Hematopoiesis Is Driven By Aberrant Activation of TCL1A
Authors: Jk Gopakumar, Joshua Weinstock, Bala B Burugula, Nikolaus Jahn, Charles Kooperberg, Pinkal Desai, Pradeep Natarajan, Jacob O Kitzman, Alexander Reiner, Alexander G. Bick, Siddhartha Jaiswal
Journal: Blood (2021)
Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia
Authors: Naranjargal J. Dashdorj, Oliver F. Wirz, Katharina Röltgen, Emily Haraguchi, Anthony S. Buzzanco, Mamdouh Sibai, Hannah Wang, Jacob A. Miller, Daniel Solis, Malaya K. Sahoo, Prabhu S. Arunachalam, Alexandra S. Lee, Mihir M. Shah, James Liu, Sumiya Byambabaatar, Purevjargal Bat-Ulzii, Anir Enkhbat, Enkhtuul Batbold, Delgersaikhan Zulkhuu, Byambasuren Ochirsum, Tungalag Khurelsukh, Ganbold Dalantai, Natsagdorj Burged, Uurtsaikh Baatarsuren, Nomin Ariungerel, Odgerel Oidovsambuu, Andreas S. Bungert, Zulkhuu Genden, Dahgwahdorj Yagaanbuyant, Altankhuu Mordorj, Bali Pulendran, Sharon Chinthrajah, Kari C. Nadeau, Theodore Jardetzky, James L. Wilbur, Jacob N. Wohlstadter, George B. Sigal, Benjamin A. Pinsky, Scott D. Boyd, Naranbaatar D. Dashdorj
Journal: Cell Host & Microbe (2021)

Different SARS-CoV-2 vaccines are approved in various countries, but few direct comparisons of the antibody responses they stimulate have been reported. We collected plasma specimens in July 2021 from 196 Mongolian participants fully vaccinated with one of four COVID-19 vaccines: Pfizer/BioNTech, AstraZeneca, Sputnik V, and Sinopharm. Functional antibody testing with a panel of nine SARS-CoV-2 viral variant receptor binding domain (RBD) proteins revealed marked differences in vaccine responses, with low antibody levels and RBD-ACE2 blocking activity stimulated by the Sinopharm and Sputnik V vaccines in comparison to the AstraZeneca or Pfizer/BioNTech vaccines. The Alpha variant caused 97% of infections in Mongolia in June and early July 2021. Individuals who recover from SARS-CoV-2 infection after vaccination achieve high antibody titers in most cases. These data suggest that public health interventions such as vaccine boosting, potentially with more potent vaccine types, may be needed to control COVID-19 in Mongolia and worldwide.